Literature DB >> 19146977

Enhanced antibody responses to Plasmodium falciparum Pfs28 induced in mice by conjugation to ExoProtein A of Pseudomonas aeruginosa with an improved procedure.

Feng Qian1, Joan A Aebig, Karine Reiter, Emma Barnafo, Yanling Zhang, Richard L Shimp, Kelly M Rausch, David S Jones, Daming Zhu, Lynn Lambert, Gregory E D Mullen, David L Narum, Louis H Miller, Yimin Wu.   

Abstract

In this paper we report our efforts to enhance the immunogenicity of Pfs28, a transmission blocking vaccine candidate of Plasmodium falciparum, using a strategy of chemical conjugation. With an improved procedure, Pfs28 was covalently coupled to the mutant and non-toxic ExoProtein A of Pseudomonas aeruginosa by the reaction between thiolated antigen and maleimide modified carrier protein. The optimized process resulted in a higher antigen-carrier conjugation ratio, and the conjugation product could be purified using single-step size-exclusion chromatography. A significant increase in immunogenicity measured by ELISA was observed in mice immunized with conjugated Pfs28 as compared to unconjugated Pfs28.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19146977      PMCID: PMC2761608          DOI: 10.1016/j.micinf.2008.12.009

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  12 in total

1.  Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex.

Authors:  Yimin Wu; Craig Przysiecki; Elizabeth Flanagan; Sheila N Bello-Irizarry; Roxana Ionescu; Olga Muratova; Gelu Dobrescu; Lynn Lambert; David Keister; Yvette Rippeon; Carole A Long; Li Shi; Michael Caulfield; Alan Shaw; Allan Saul; John Shiver; Louis H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-16       Impact factor: 11.205

2.  Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide.

Authors:  Gregory E D Mullen; Birgitte K Giersing; Olubunmi Ajose-Popoola; Heather L Davis; Cheryl Kothe; Hong Zhou; Joan Aebig; Gelu Dobrescu; Allan Saul; Carole A Long
Journal:  Vaccine       Date:  2006-01-04       Impact factor: 3.641

3.  Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines.

Authors:  Kazutoyo Miura; Andrew C Orcutt; Olga V Muratova; Louis H Miller; Allan Saul; Carole A Long
Journal:  Vaccine       Date:  2007-11-20       Impact factor: 3.641

Review 4.  Mosquito stage, transmission blocking vaccines for malaria.

Authors:  Allan Saul
Journal:  Curr Opin Infect Dis       Date:  2007-10       Impact factor: 4.915

5.  A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines.

Authors:  P E Duffy; D C Kaslow
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

6.  Production and characterization of clinical grade Escherichia coli derived Plasmodium falciparum 42 kDa merozoite surface protein 1 (MSP1(42)) in the absence of an affinity tag.

Authors:  Richard L Shimp; Laura B Martin; Yanling Zhang; Brian S Henderson; Peter Duggan; Nicholas J MacDonald; Jacob Lebowitz; Allan Saul; David L Narum
Journal:  Protein Expr Purif       Date:  2006-06-27       Impact factor: 1.650

7.  Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.

Authors:  Feng Qian; Kelly M Rausch; Olga Muratova; Hong Zhou; Guanhong Song; Ababacar Diouf; Lynn Lambert; David L Narum; Yimin Wu; Allan Saul; Louis H Miller; Carole A Long; Gregory E D Mullen
Journal:  Vaccine       Date:  2008-03-27       Impact factor: 3.641

8.  A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains.

Authors:  D C Kaslow; I A Quakyi; C Syin; M G Raum; D B Keister; J E Coligan; T F McCutchan; L H Miller
Journal:  Nature       Date:  1988-05-05       Impact factor: 49.962

9.  Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25.

Authors:  Joanna Kubler-Kielb; Fathy Majadly; Yimin Wu; David L Narum; Chunyan Guo; Louis H Miller; Joseph Shiloach; John B Robbins; Rachel Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-26       Impact factor: 12.779

10.  Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates.

Authors:  Feng Qian; Yimin Wu; Olga Muratova; Hong Zhou; Gelu Dobrescu; Peter Duggan; Lambert Lynn; Guanhong Song; Yanling Zhang; Karine Reiter; Nicholas MacDonald; David L Narum; Carole A Long; Louis H Miller; Allan Saul; Gregory E D Mullen
Journal:  Vaccine       Date:  2007-03-13       Impact factor: 4.169

View more
  11 in total

1.  Determination of protein concentration for protein-protein conjugates using ultraviolet absorption.

Authors:  Daming Zhu; Feng Qian; Yimin Wu; David S Jones; Christopher Rowe; David L Narum; Patrick Duffy; Louis H Miller; Allan Saul
Journal:  J Immunol Methods       Date:  2012-10-23       Impact factor: 2.303

2.  Comparative Genomics and Systems Biology of Malaria Parasites Plasmodium.

Authors:  Hong Cai; Zhan Zhou; Jianying Gu; Yufeng Wang
Journal:  Curr Bioinform       Date:  2012-12-01       Impact factor: 3.543

Review 3.  Particle-based platforms for malaria vaccines.

Authors:  Yimin Wu; David L Narum; Sylvain Fleury; Gary Jennings; Anjali Yadava
Journal:  Vaccine       Date:  2015-10-11       Impact factor: 3.641

4.  Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission.

Authors:  James A Gregory; Fengwu Li; Lauren M Tomosada; Chesa J Cox; Aaron B Topol; Joseph M Vinetz; Stephen Mayfield
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

5.  Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1.

Authors:  Feng Qian; Karine Reiter; Yanling Zhang; Richard L Shimp; Vu Nguyen; Joan A Aebig; Kelly M Rausch; Daming Zhu; Lynn Lambert; Gregory E D Mullen; Laura B Martin; Carole A Long; Louis H Miller; David L Narum
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

6.  The biology of sexual development of Plasmodium: the design and implementation of transmission-blocking strategies.

Authors:  Robert E Sinden; Richard Carter; Chris Drakeley; Didier Leroy
Journal:  Malar J       Date:  2012-03-16       Impact factor: 2.979

Review 7.  Strategies & recent development of transmission-blocking vaccines against Plasmodium falciparum.

Authors:  Neha Chaturvedi; Praveen K Bharti; Archana Tiwari; Neeru Singh
Journal:  Indian J Med Res       Date:  2016-06       Impact factor: 2.375

8.  Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity.

Authors:  Puthupparampil V Scaria; Beth Chen; Christopher G Rowe; David S Jones; Emma Barnafo; Elizabeth R Fischer; Charles Anderson; Nicholas J MacDonald; Lynn Lambert; Kelly M Rausch; David L Narum; Patrick E Duffy
Journal:  PLoS One       Date:  2017-12-27       Impact factor: 3.240

9.  Assessment of Antibodies Induced by Multivalent Transmission-Blocking Malaria Vaccines.

Authors:  Vinay Menon; Melissa C Kapulu; Iona Taylor; Kerry Jewell; Yuanyuan Li; Fergal Hill; Carole A Long; Kazutoyo Miura; Sumi Biswas
Journal:  Front Immunol       Date:  2018-01-19       Impact factor: 7.561

10.  A Method for Producing Protein Nanoparticles with Applications in Vaccines.

Authors:  David S Jones; Christopher G Rowe; Beth Chen; Karine Reiter; Kelly M Rausch; David L Narum; Yimin Wu; Patrick E Duffy
Journal:  PLoS One       Date:  2016-03-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.